Rathbone J, Zhang L, Zhang M, Xia J, Liu Xiehe, Yang Yanchun
Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD003444. doi: 10.1002/14651858.CD003444.pub2.
Traditional Chinese medicine (TCM) was the main form of treatment in China for psychiatric illnesses until the development of antipsychotic drugs in the 1950's. Antipsychotic drugs have become the primary intervention for schizophrenia, although herbal medicines can still form part of the treatment.
To review Chinese herbal medicine, used alone or as part of a TCM approach, for people with schizophrenia and related psychoses.
We undertook electronic searches of the Cochrane Schizophrenia Group's register (December 2003), the Traditional Chinese Medical Literature Analysis and Retrieval Database (TCMLARS) (October 2003), Chinese Biomedical Database (CBM) (December 2003), China National Knowledge Infrastructure Database (May 2004), Complementary Medicine Database (AMED) (December 2003). We contacted the Chinese Cochrane Centre, the Cochrane Complementary Medicine Field and first authors of included studies and inspected reference lists for additional studies.
We included all relevant randomised controlled trials involving people with schizophrenia-like illnesses, allocated to Chinese herbal medicine, including any Chinese herbs (single or mixture), compared with placebo/no treatment or antipsychotic drugs.
We independently extracted data and calculated fixed effects relative risk (RR), the 95% confidence intervals (CI) for homogeneous dichotomous data, and, where appropriate, the number needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).
Only one small trial of the seven included studies truly evaluated TCM for schizophrenia. The other trials evaluated Chinese herbs for schizophrenia. We found one study comparing Chinese herbal medicine with antipsychotic drugs. Data for the global state outcome 'no change/worse' favoured people allocated to antipsychotic medication (n=90, RR 1.88 CI 1.2 to 2.9, NNH 4 CI 2 to 12). Six trials compared Chinese herbal medicine in combination with antipsychotic with antipsychotic drugs alone. One trial found global state 'not improved/worse' favoured the herbal medicine/antipsychotic combination (n=123, RR 0.19 CI 0.1 to 0.6, NNT 6 CI 5 to 11). Two studies (n=103) also found short-term data from the Clinical Global Impression scale favoured the herbal medicine plus antipsychotic group (WMD -0.46 CI -0.9 to -0.1) compared with those given only antipsychotics. Significantly fewer people in the experimental group left the study early compared with those given antipsychotics alone (n=1004, 6 RCTs, RR 0.30 CI 0.16 to 0.58, NNT 21 CI 18 to 35). Reports of constipation were significantly lower in the treatment group compared to those receiving antipsychotics (n=67, 1 RCT, RR 0.03 CI 0.0 to 0.5, NNH 2 CI 2 to 4).
AUTHORS' CONCLUSIONS: Chinese herbal medicines, given in a Western biomedical context, may be beneficial for people with schizophrenia when combined with antipsychotics. Traditional Chinese medicine is also under-evaluated, but results from one pioneering study that attempted to evaluate TCM should encourage further trials.
在20世纪50年代抗精神病药物出现之前,传统中医是中国治疗精神疾病的主要方式。尽管草药仍可作为治疗的一部分,但抗精神病药物已成为治疗精神分裂症的主要干预手段。
综述单独使用或作为中医治疗方法一部分的中草药对精神分裂症及相关精神病患者的疗效。
我们对Cochrane精神分裂症研究组注册库(2003年12月)、中国传统医学文献分析与检索数据库(TCMLARS)(2003年10月)、中国生物医学文献数据库(CBM)(2003年12月)、中国知网数据库(2004年5月)、补充医学数据库(AMED)(2003年12月)进行了电子检索。我们联系了中国Cochrane中心、Cochrane补充医学领域以及纳入研究的第一作者,并查阅参考文献列表以寻找其他研究。
我们纳入了所有涉及精神分裂症样疾病患者的相关随机对照试验,将其分配至中草药治疗组,包括任何中草药(单一或混合),并与安慰剂/未治疗组或抗精神病药物进行比较。
我们独立提取数据,并计算固定效应相对危险度(RR)、同质二分数据的95%置信区间(CI),并在适当情况下,计算意向性分析的需治疗人数(NNT)。对于连续性数据,我们计算加权均数差(WMD)。
纳入的七项研究中,仅有一项小型试验真正评估了中医对精神分裂症的疗效。其他试验评估了中草药对精神分裂症的疗效。我们发现一项研究比较了中草药与抗精神病药物。关于“无变化/恶化”的总体状态数据显示,分配至抗精神病药物治疗组的患者情况更佳(n = 90,RR 1.88,CI 1.2至2.9,NNH 4,CI 2至12)。六项试验比较了中草药联合抗精神病药物与单纯抗精神病药物。一项试验发现,总体状态“未改善/恶化”的情况在中草药/抗精神病药物联合治疗组更佳(n = 123,RR 0.19,CI 0.1至0.6,NNT 6,CI 5至11)。两项研究(n = 103)还发现,来自临床总体印象量表的短期数据显示,与仅接受抗精神病药物治疗的患者相比,中草药加抗精神病药物组情况更佳(WMD -0.46,CI -0.9至-0.1)。与仅接受抗精神病药物治疗的患者相比,试验组提前退出研究的人数明显更少(n = 1004,6项随机对照试验,RR 0.30,CI 0.16至0.58,NNT 21,CI 18至35)。与接受抗精神病药物治疗的患者相比,治疗组便秘报告明显更少(n = 67,1项随机对照试验,RR 0.03,CI 0.0至0.5,NNH 2,CI 2至4)。
在西方生物医学背景下,中草药与抗精神病药物联合使用可能对精神分裂症患者有益。传统中医也未得到充分评估,但一项尝试评估中医的开创性研究结果应会鼓励进一步的试验。